Monoclonal antibody therapy-associated neurological disorders

Nature Reviews Neurology

Volumn 7, Issue 3, 2011, Pages 165-172

  Bosch, Xavier ^a   Saiz, Albert ^a   Ramos Casals, Manuel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; EFALIZUMAB; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTHRITIS; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CAUSAL ATTRIBUTION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; CROHN DISEASE; DEMYELINATING DISEASE; DEMYELINATING NEUROPATHY; DRUG WITHDRAWAL; GOODPASTURE SYNDROME; GRAVES DISEASE; GUILLAIN BARRE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MONONEUROPATHY MULTIPLEX; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYELITIS; NEUROLOGIC DISEASE; OPTIC NEURITIS; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT CARE; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; POLYRADICULONEUROPATHY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; DEMYELINATING DISEASES; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; NERVOUS SYSTEM DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; PRODUCT SURVEILLANCE, POSTMARKETING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952573321     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2011.1     Document Type: Review

References (44)

1. Novak, J. C., Lovett-Rache, A. E. & Rache, M. K. Monoclonal antibody therapies and neurologic disorders. Arch. Neurol. 65, 1162-1165 (2008).
2. Ramos-Casals, M., Brito-Zerón, P, Soto, M. J., Cuadrado, M. J. & Khamashta, M. A. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res. Clin. Rheumatol. 22, 847-861 (2008).
3. Faivre A. et al. Acute motor and sensory axonal neuropathy and concomitant encephalopathy during tumor necrosis factor-alpha antagonist therapy J. Neurol. Sci. 291, 103-106 (2010)
4. BIOGEAS [online], http://www.biogeas.org/eng/objetivo.html (2007).
5. Ramos-Casals, M. et al. Autoimmune diseases induced by biological agents. A double-edged sword? Autoimmun. Rev. 9, 188-193 (2010).
6. Ramos-Casals, M. et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86, 242-251 (2007). (Pubitemid 47067483)
7. Ramos-Casals, M., Brito-Zerón, P, Cuadrado, M. J. & Khamashta, M. A. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr. Rheumatol. Rep. 10, 442-448 (2008).
8. Weissert R. Progressive multifocal leukoencephalopathy. J. Neuroimmunol. doi:10.1016/j.jneuroim.2010.09.021.
9. Tyler, K. L. Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological mmunomodulatory therapies? Ann. Neurol. 68, 271-274 (2010).
10. Bielekova, B. & Becker, B. L. Monoclonal antibodies in MS. Mechanisms of action. Neurology 74 (Suppl. 1), S31-S40 (2010)
11. The CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786-1801 (2008).
12. Paolillo, A. et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53, 751-757 (1999). (Pubitemid 29448295)
13. Moreau, T. et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344, 298-301 (1994). (Pubitemid 24230297)
14. Piccinni, C et al. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological mmunomodulating agents. Eur. J. Clin. Pharmacol. 66, 199-206 (2010).
15. Allen, J. A., Adlakha, A. & Bergethon, P R. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch. Neurol. 63, 1475-1478 (2006). (Pubitemid 44547561)
16. Glusker, P, Recht, L. & Lane, B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 354, 980-981 (2006).
17. van Oosten, B. W. et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47, 1531-1534 (1996). (Pubitemid 26422549)
18. [No authors listed] TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53, 457-465 (1999).
19. Chung, J. H. et al. Adalimumab-associated optic neuritis. J. Neurol. Sci. 244, 133-136 (2006).
20. Bernatsky, S., Renoux, C & Suissa, S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann. Rheum. Dis. 69, 1691-1693 (2010).
21. Stübgen, J. P Tumor necrosis factor-α antagonists and neuropathy. Muscle Nerve 37, 281-292 (2008). (Pubitemid 351304787)
22. Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G. & Tak, P P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244-279 (2008).
23. Shin, I. S., Baer, A., Kwon, H., Papadopoulos, E. & Siegel, J. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor α antagonist therapy. Arthritis Rheum. 54, 1429-1434 (2006).
24. Lozeron, P, Denier, C., Lacroix, C & Adams, D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-α- blocker therapy Arch. Neurol. 66, 490-497 (2009).
25. Alshekhlee, A., Basiri, K., Miles, J. D., Ahmad, S. A. & Katirji, B. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-α antagonists. Muscle Nerve 41, 723-727 (2010).
26. Birnbaum, J. Infliximab associated neuropathy in RA patients\the importance of considering the diagnosis of mononeuritis multiplex. Clin. Rheumatol. 26, 281-282 (2007). (Pubitemid 46020264)
27. Singer, O. C., Otto, B., Steinmetz, H. & Ziemann, U. Acute neuropathy with multiple conduction blocks after TNFα monoclonal antibody therapy. Neurology 63, 1754 (2004). (Pubitemid 39507613)
28. rd, Sander, H. W., Chin, R. I. & Latov, N. Peripheral neuropathy in patients with inflammatory bowel disease. Brain 128, 867-879 (2005). (Pubitemid 40516923)
29. Miller, F W. et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum. 43, 243-249 (2000).
30. Tektonidou, M. G., Serelis, J. & Skopouli, F M. Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. Clin. Rheumatol. 26, 258-260 (2007). (Pubitemid 46020257)
31. Jarrett, S. J. et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J. Rheumatol. 30, 2287-2291 (2003). (Pubitemid 37221866)
32. Richette, P. et al. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J. Rheumatol. 31, 2079-2081 (2004). (Pubitemid 39336740)
33. Cisternas, M., Gutiérrez, M. & Jacobelli, S. Successful rechallenge with anti-tumor necrosis factor α for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment. Arthritis Rheum. 46, 3107-3108 (2002).
34. Richez, C Blanco, P, Lagueny, A., Schaeverbeke, T & Dehais, J. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-α blockers. Neurology 64, 1468-1470 (2005). (Pubitemid 40570527)
35. Hooper, D. R., Tarnopolsky, M. A. & Baker, S. K. Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis. Muscle Nerve 38, 1318-1325 (2008).
36. Chen, Y et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med. 361, 1067-1074 (2009).
37. Major, E. O. Reemergence of PML in natalizumab-treated patients\new cases, same concerns. N. Engl. J. Med. 361, 1041-1043 (2009).
38. Xu, L. et al. The polymorphisms of the TNF-α gene in multiple sclerosis?\a meta-analysis. Mol. Biol. Rep. doi:10.1007/s11033-010-0533-0.
39. Bachmann, R., Eugster, H. P, Frei, K., Fontana, A. & Lassmann, H. Impairment of TNF-receptor-1 signaling but not Fas signaling diminishes T-cel apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice. Am. J. Pathol. 154, 1417-1422 (1999). (Pubitemid 29226436)
40. Wenning, W. et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N. Engl. J. Med. 361, 1075-1080 (2009).
41. Schiff, M. H. et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis. 65, 889-894 (2006).
42. Burmester, G. R. et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann. Rheum. Dis. 66, 732-739 (2007). (Pubitemid 46846691)
43. Colombel, J. F et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis. 15, 1308-1319 (2009).
44. Magnano, M. D., Robinson, W. H. & Genovese, M. C Demyelination and inhibition of tumor necrosis factor (TNF). Clin. Exp. Rheumatol. 22 (Suppl. 35), S134-S140 (2004) (Pubitemid 39328366)